Matches in SemOpenAlex for { <https://semopenalex.org/work/W2105909738> ?p ?o ?g. }
Showing items 1 to 63 of
63
with 100 items per page.
- W2105909738 endingPage "A327" @default.
- W2105909738 startingPage "A327" @default.
- W2105909738 abstract "Inhibitor development is one of the most important and expensive adverse event in patients with severe hemophilia A. A different incidence between second or third generation FVIII determine different resource consumption in long term therapy. The Pass study aimed to assess the break-even point in patients treated with ADVATE® or with another second or third generation (FVIII X), considering effects on direct medical cost attributable to different inhibitors development. A model based on Oldenburg 2010 study population characteristic( 348 Pre Treated Patients; FVIII ≤2%; no previous inhibitor stories) was developed comparing costs generate from ADAVATE® treatment vs “FVIII X”. We considered a time horizon of 5 years and the National Health System's (NHS) point of view. In order to assess the validity of the break-even point estimate, a sensitivity analysis was conducted modifying the percentages of patients allocated to prophylaxis or on demand regimen. According to model results the overall cost during 5 years was: 243,966,787.44€ for ADAVATE® treatment and 223,402,102.06€ for “FVIII X” treatment. To gain the break-even point between ADAVATE® and “FVIII X”, the number of patients who should develop inhibitors was 4.98(1.43%) in 5 years. If all patients were allocated to prophylaxis regimen, to gain the break-even point the number of patients who should develop inhibitors was 9.68(2.78%). On the other hand for on demand treatment it should be 1.29(0.37%). Considering the high cost generated by inhibitor development and the lack of direct comparing studies in scientific literature, the Pass Study provided interesting information for decision makers in order to manage properly patients care. Inhibitor development should be more considered during decision process, as an expensive adverse event in hemophilic A patients treatment. A direct comparing study is necessary to obtain more consistent results." @default.
- W2105909738 created "2016-06-24" @default.
- W2105909738 creator A5019707828 @default.
- W2105909738 creator A5036479504 @default.
- W2105909738 creator A5046959234 @default.
- W2105909738 creator A5053344192 @default.
- W2105909738 creator A5063888848 @default.
- W2105909738 creator A5081162921 @default.
- W2105909738 date "2012-11-01" @default.
- W2105909738 modified "2023-09-25" @default.
- W2105909738 title "PGI8 Second and Third Generation FVIII Treatment Resources Consumption Break-Even Point: The Pass Study Results" @default.
- W2105909738 doi "https://doi.org/10.1016/j.jval.2012.08.757" @default.
- W2105909738 hasPublicationYear "2012" @default.
- W2105909738 type Work @default.
- W2105909738 sameAs 2105909738 @default.
- W2105909738 citedByCount "0" @default.
- W2105909738 crossrefType "journal-article" @default.
- W2105909738 hasAuthorship W2105909738A5019707828 @default.
- W2105909738 hasAuthorship W2105909738A5036479504 @default.
- W2105909738 hasAuthorship W2105909738A5046959234 @default.
- W2105909738 hasAuthorship W2105909738A5053344192 @default.
- W2105909738 hasAuthorship W2105909738A5063888848 @default.
- W2105909738 hasAuthorship W2105909738A5081162921 @default.
- W2105909738 hasBestOaLocation W21059097381 @default.
- W2105909738 hasConcept C120665830 @default.
- W2105909738 hasConcept C121332964 @default.
- W2105909738 hasConcept C126322002 @default.
- W2105909738 hasConcept C197934379 @default.
- W2105909738 hasConcept C2781413609 @default.
- W2105909738 hasConcept C2908647359 @default.
- W2105909738 hasConcept C61511704 @default.
- W2105909738 hasConcept C71924100 @default.
- W2105909738 hasConcept C99454951 @default.
- W2105909738 hasConceptScore W2105909738C120665830 @default.
- W2105909738 hasConceptScore W2105909738C121332964 @default.
- W2105909738 hasConceptScore W2105909738C126322002 @default.
- W2105909738 hasConceptScore W2105909738C197934379 @default.
- W2105909738 hasConceptScore W2105909738C2781413609 @default.
- W2105909738 hasConceptScore W2105909738C2908647359 @default.
- W2105909738 hasConceptScore W2105909738C61511704 @default.
- W2105909738 hasConceptScore W2105909738C71924100 @default.
- W2105909738 hasConceptScore W2105909738C99454951 @default.
- W2105909738 hasIssue "7" @default.
- W2105909738 hasLocation W21059097381 @default.
- W2105909738 hasOpenAccess W2105909738 @default.
- W2105909738 hasPrimaryLocation W21059097381 @default.
- W2105909738 hasRelatedWork W1580426574 @default.
- W2105909738 hasRelatedWork W1970383787 @default.
- W2105909738 hasRelatedWork W2043123170 @default.
- W2105909738 hasRelatedWork W2089045987 @default.
- W2105909738 hasRelatedWork W2089620537 @default.
- W2105909738 hasRelatedWork W2275480158 @default.
- W2105909738 hasRelatedWork W2409957712 @default.
- W2105909738 hasRelatedWork W3095306390 @default.
- W2105909738 hasRelatedWork W4238089809 @default.
- W2105909738 hasRelatedWork W4241346791 @default.
- W2105909738 hasVolume "15" @default.
- W2105909738 isParatext "false" @default.
- W2105909738 isRetracted "false" @default.
- W2105909738 magId "2105909738" @default.
- W2105909738 workType "article" @default.